Status Quo and Medical Need

A significant proportion of patients affected by or people at risk for cardiometabolic diseases are undiagnosed. Treatment refractory disease and rising health care costs are also matters of concern. The finding that health promoting and disease preventing lifestyle interventions need to be highly individualized, further highlight the need for new and better biomarkers.

Metabolic phenotyping has been playing a large role in developing promising markers at any stage of cardiometabolic diseases– whether it‘s prediction, diagnosis, or disease monitoring. Metabolic research has also helped in understanding the pathophysiological mechanisms involved, and will continue to do so. Biocrates’ focus on low sample requirement, high throughput and reproducibility facilitates bench-to-bedside research strategies.